4.00
+0.01(+0.25%)
Currency In USD
| Previous Close | 3.99 |
| Open | 4 |
| Day High | 4 |
| Day Low | 3.99 |
| 52-Week High | 6.24 |
| 52-Week Low | 0.72 |
| Volume | 1.46M |
| Average Volume | 2.26M |
| Market Cap | 258.25M |
| PE | -2.38 |
| EPS | -1.68 |
| Moving Average 50 Days | 2.85 |
| Moving Average 200 Days | 2.79 |
| Change | 0.01 |
If you invested $1000 in Inozyme Pharma, Inc. (INZY) since IPO date, it would be worth $228.05 as of July 02, 2025 at a share price of $4. Whereas If you bought $1000 worth of Inozyme Pharma, Inc. (INZY) shares 3 years ago, it would be worth $865.8 as of July 02, 2025 at a share price of $4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
GlobeNewswire Inc.
Jun 20, 2025 9:00 PM GMT
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the pre
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
GlobeNewswire Inc.
Apr 10, 2025 12:30 PM GMT
Phenotypic Characterization of ENPP1 Deficiency JBMR image of the phenotypic characterization of ENPP1 Deficiency - Data from the largest retrospective analysis of ENPP1 Deficiency provides insights into the evolution of the disease’s serious car
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Mar 31, 2025 12:30 PM GMT
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel fu
Data not available